Best Biotech Stocks to Buy Now (2024)Top biotech stocks in 2024 ranked by overall Zen Score. See the best biotech stocks to buy now, according to analyst forecasts for the biotechnology industry.
Industry: Biotechnology
| Ticker | Company | Country | Market Cap | Shares | Institutional % | Insider % | Net Insider (L12M) | Net Insider (L3M) |
|---|---|---|---|---|---|---|---|---|
| IFRX | INFLARX NV | Germany | $81.26M | 58,883,272 | 29.00% | 0.00% | ||
| LQDA | LIQUIDIA CORP | United States | $972.40M | 76,027,776 | 37.70% | 62.30% | Net Buying | Net Selling |
| ATAI | ATAI LIFE SCIENCES NV | United States | $340.35M | 166,026,396 | 7.99% | 37.92% | Net Selling | Net Selling |
| GLMD | GALMED PHARMACEUTICALS LTD | Israel | $1.95M | 5,045,324 | 10.84% | 0.00% | ||
| AUPH | AURINIA PHARMACEUTICALS INC | Canada | $729.40M | 143,019,365 | 37.21% | 3.22% | Net Selling | Net Selling |
| BEAM | BEAM THERAPEUTICS INC | United States | $1.89B | 81,657,714 | 78.56% | 21.44% | Net Selling | Net Selling |
| CASI | CASI PHARMACEUTICALS INC | China | $37.39M | 13,378,175 | 0.35% | 99.65% | ||
| NRBO | NEUROBO PHARMACEUTICALS INC | United States | $18.54M | 4,906,032 | 0.25% | 99.75% | ||
| BLUE | BLUEBIRD BIO INC | United States | $98.40M | 109,336,211 | 91.17% | 8.83% | Net Selling | Net Selling |
| HOTH | HOTH THERAPEUTICS INC | United States | $5.33M | 4,403,804 | 0.94% | 99.06% | ||
| MTEM | MOLECULAR TEMPLATES INC | United States | $8.98M | 5,374,268 | 1.90% | 98.10% | Net Buying | Net Buying |
| ARVN | ARVINAS INC | United States | $2.23B | 68,083,928 | 74.74% | 25.26% | Net Selling | Net Selling |
| MESO | MESOBLAST LTD | Australia | $761.10M | 1,014,799,334 | 0.14% | 0.00% | ||
| CRBU | CARIBOU BIOSCIENCES INC | United States | $340.49M | 90,314,501 | 76.47% | 8.74% | Net Buying | |
| YMAB | Y-MABS THERAPEUTICS INC | United States | $750.78M | 43,777,105 | 46.22% | 39.32% | Net Buying | Net Selling |
| LIFE | ATYR PHARMA INC | United States | $111.11M | 69,010,940 | 59.74% | 22.13% | Net Buying | |
| CUE | CUE BIOPHARMA INC | United States | $103.61M | 48,643,316 | 30.60% | 9.31% | Net Buying | |
| PGEN | PRECIGEN INC | United States | $353.47M | 248,919,096 | 25.15% | 73.45% | Net Buying | Net Selling |
| CCCC | C4 THERAPEUTICS INC | United States | $462.37M | 68,600,669 | 68.39% | 25.32% | Net Buying | Net Selling |
| ARDX | ARDELYX INC | United States | $2.04B | 233,976,572 | 38.01% | 61.99% | Net Selling | Net Selling |
| IKNA | IKENA ONCOLOGY INC | United States | $63.70M | 48,258,111 | 66.60% | 18.22% | ||
| CELZ | CREATIVE MEDICAL TECHNOLOGY HOLDINGS INC | United States | $5.96M | 1,356,626 | 1.45% | 3.94% | Net Buying | |
| LYRA | LYRA THERAPEUTICS INC | United States | $245.69M | 60,964,859 | 69.46% | 14.19% | Net Buying | |
| QTTB | Q32 BIO INC | United States | $82.65M | 3,229,641 | 47.15% | 52.85% | Net Selling | Net Selling |
| ALLO | ALLOGENE THERAPEUTICS INC | United States | $519.11M | 169,091,992 | 60.42% | 39.58% | Net Selling | Net Selling |
| MIST | MILESTONE PHARMACEUTICALS INC | Canada | $89.82M | 53,149,778 | 33.44% | 24.16% | ||
| PRTC | PURETECH HEALTH PLC | United States | $773.99M | 271,853,731 | 0.00% | 0.00% | ||
| XOMA | XOMA CORP | United States | $288.09M | 11,625,826 | 17.69% | 82.31% | Net Buying | |
| NTLA | INTELLIA THERAPEUTICS INC | United States | $2.27B | 96,106,405 | 68.92% | 31.08% | Net Selling | Net Selling |
| PLUR | PLURI INC | Israel | $29.81M | 5,185,022 | 0.58% | 99.42% | ||
| ARQT | ARCUTIS BIOTHERAPEUTICS INC | United States | $774.51M | 96,813,363 | 73.16% | 26.84% | Net Buying | Net Selling |
| DNLI | DENALI THERAPEUTICS INC | United States | $2.39B | 139,160,239 | 56.52% | 43.48% | Net Selling | Net Selling |
| LYEL | LYELL IMMUNOPHARMA INC | United States | $599.67M | 254,096,311 | 51.66% | 46.21% | Net Selling | |
| SPRC | SCISPARC LTD | Israel | $890.42k | 706,683 | 1.05% | 0.00% | ||
| IMNM | IMMUNOME INC | United States | $940.18M | 59,694,243 | 36.00% | 9.90% | Net Buying | |
| KROS | KEROS THERAPEUTICS INC | United States | $2.18B | 35,982,628 | 70.92% | 29.08% | Net Buying | |
| GLYC | GLYCOMIMETICS INC | United States | $117.94M | 64,450,385 | 35.53% | 64.47% | Net Buying | Net Buying |
| INO | INOVIO PHARMACEUTICALS INC | United States | $282.78M | 23,370,365 | 61.56% | 38.44% | Net Selling | Net Selling |
| MRNS | MARINUS PHARMACEUTICALS INC | United States | $82.51M | 54,642,580 | 81.93% | 18.07% | Net Buying | Net Buying |
| ABCL | ABCELLERA BIOLOGICS INC | Canada | $1.18B | 292,782,152 | 40.68% | 47.55% | Net Buying | Net Buying |
| OVID | OVID THERAPEUTICS INC | United States | $216.37M | 70,709,857 | 62.41% | 23.75% | Net Buying | Net Buying |
| EDIT | EDITAS MEDICINE INC | United States | $463.88M | 81,813,850 | 64.04% | 35.96% | Net Selling | Net Selling |
| COCP | COCRYSTAL PHARMA INC | United States | $16.58M | 10,173,790 | 0.69% | 99.31% | ||
| PALI | PALISADE BIO INC | United States | $6.59M | 851,401 | 3.08% | 96.92% | Net Buying | |
| CRNX | CRINETICS PHARMACEUTICALS INC | United States | $3.28B | 69,596,202 | 85.00% | 15.00% | Net Selling | Net Selling |
| ALEC | ALECTOR INC | United States | $516.09M | 95,749,259 | 58.13% | 41.87% | Net Selling | Net Selling |
| ALPN | ALPINE IMMUNE SCIENCES INC | United States | $4.23B | 65,546,136 | 58.72% | 41.28% | Net Buying | Net Buying |
| STTK | SHATTUCK LABS INC | United States | $512.60M | 47,550,872 | 56.87% | 26.45% | Net Selling | Net Selling |
| GERN | GERON CORP | United States | $2.33B | 593,132,540 | 66.32% | 1.13% | Net Buying | |
| GBIO | GENERATION BIO CO | United States | $210.73M | 66,477,111 | 63.23% | 36.77% | Net Buying | Net Selling |
| MGNX | MACROGENICS INC | United States | $978.31M | 62,432,013 | 72.54% | 27.46% | Net Buying | Net Selling |
| PPBT | PURPLE BIOTECH LTD | Israel | $10.51M | 198,386,080 | 1.23% | 0.00% | ||
| ABSI | ABSCI CORP | United States | $572.95M | 112,784,576 | 29.91% | 39.04% | Net Buying | Net Buying |
| LUMO | LUMOS PHARMA INC | United States | $24.00M | 8,107,121 | 17.70% | 82.30% | Net Buying | Net Buying |
| KYMR | KYMERA THERAPEUTICS INC | United States | $2.29B | 61,358,262 | 71.48% | 28.52% | Net Selling | Net Selling |
| IMAB | I-MAB | China | $142.11M | 185,613,662 | 6.65% | 0.00% | ||
| MRNA | MODERNA INC | United States | $47.90B | 383,239,726 | 67.09% | 21.59% | Net Selling | Net Selling |
| QURE | UNIQURE NV | Netherlands | $224.36M | 47,838,275 | 78.37% | 13.99% | Net Selling | Net Selling |
| CVKD | CADRENAL THERAPEUTICS INC | United States | $7.84M | 16,008,469 | 3.45% | 46.72% | Net Buying | |
| SXTP | 60 DEGREES PHARMACEUTICALS INC | United States | $2.43M | 11,570,578 | 4.00% | 31.34% | Net Buying | |
| NGNE | NEUROGENE INC | United States | $470.80M | 12,852,985 | 36.48% | 63.52% | Net Buying | |
| BPMC | BLUEPRINT MEDICINES CORP | United States | $6.71B | 62,616,902 | 81.64% | 18.36% | Net Selling | Net Selling |
| ATOS | ATOSSA THERAPEUTICS INC | United States | $208.00M | 125,304,064 | 12.74% | 15.22% | Net Buying | Net Buying |
| EVGN | EVOGENE LTD | Israel | $35.92M | 50,584,588 | 8.48% | 0.00% | ||
| ELVN | ENLIVEN THERAPEUTICS INC | United States | $936.52M | 41,347,632 | 46.22% | 53.78% | Net Selling | Net Selling |
| DTIL | PRECISION BIOSCIENCES INC | United States | $72.76M | 6,916,239 | 56.40% | 43.60% | Net Selling | Net Selling |
| CLDX | CELLDEX THERAPEUTICS INC | United States | $2.38B | 55,900,679 | 82.75% | 17.25% | Net Buying | Net Buying |
| DMAC | DIAMEDICA THERAPEUTICS INC | United States | $113.87M | 37,958,000 | 10.12% | 55.46% | Net Buying | |
| SVRA | SAVARA INC | United States | $649.99M | 138,148,141 | 32.26% | 67.74% | Net Buying | Net Selling |
| TCRX | TSCAN THERAPEUTICS INC | United States | $409.87M | 47,882,196 | 66.65% | 29.73% | Net Buying | |
| AVXL | ANAVEX LIFE SCIENCES CORP | United States | $316.13M | 82,112,511 | 31.49% | 5.04% | Net Buying | Net Buying |
| TBPH | THERAVANCE BIOPHARMA INC | Cayman Islands | $455.64M | 48,164,708 | 59.18% | 40.82% | Net Buying | Net Buying |
| DNTH | DIANTHUS THERAPEUTICS INC | United States | $757.15M | 29,346,760 | 24.91% | 75.09% | Net Buying | |
| NTBL | NOTABLE LABS LTD | Israel | $8.57M | 9,018,261 | 2.63% | 97.37% | Net Selling | |
| CRDF | CARDIFF ONCOLOGY INC | United States | $157.43M | 44,724,591 | 11.84% | 34.56% | Net Buying | |
| TTNP | TITAN PHARMACEUTICALS INC | United States | $6.29M | 914,234 | 2.50% | 97.50% | Net Selling | |
| MOLN | MOLECULAR PARTNERS AG | Switzerland | $130.76M | 32,854,297 | 2.91% | 0.00% | ||
| LABP | LANDOS BIOPHARMA INC | United States | $69.30M | 3,116,729 | 4.53% | 95.47% | ||
| PMCB | PHARMACYTE BIOTECH INC | United States | $17.86M | 8,464,824 | 12.86% | 13.29% | ||
| FDMT | 4D MOLECULAR THERAPEUTICS INC | United States | $1.31B | 49,778,127 | 83.80% | 16.20% | Net Buying | Net Selling |
| LSTA | LISATA THERAPEUTICS INC | United States | $23.68M | 8,307,433 | 0.84% | 99.16% | Net Selling | |
| TRVI | TREVI THERAPEUTICS INC | United States | $208.26M | 68,960,167 | 22.22% | 77.78% | Net Buying | |
| BOLT | BOLT BIOTHERAPEUTICS INC | United States | $41.94M | 38,127,740 | 54.74% | 45.26% | Net Selling | |
| ETNB | 89BIO INC | United States | $862.08M | 93,501,210 | 85.97% | 14.03% | Net Buying | Net Buying |
| TVTX | TRAVERE THERAPEUTICS INC | United States | $476.38M | 76,098,485 | 59.75% | 40.25% | Net Selling | Net Selling |
| AKRO | AKERO THERAPEUTICS INC | United States | $1.11B | 56,297,528 | 66.83% | 33.17% | Net Buying | Net Buying |
| SNSE | SENSEI BIOTHERAPEUTICS INC | United States | $44.88M | 25,070,980 | 11.82% | 71.99% | Net Selling | Net Selling |
| RIGL | RIGEL PHARMACEUTICALS INC | United States | $210.45M | 175,377,812 | 60.76% | 15.75% | Net Selling | |
| ATXS | ASTRIA THERAPEUTICS INC | United States | $524.32M | 54,903,061 | 67.13% | 25.09% | Net Buying | Net Buying |
| DNA | GINKGO BIOWORKS HOLDINGS INC | United States | $2.06B | 2,152,395,786 | 58.22% | 13.98% | Net Selling | Net Selling |
| TERN | TERNS PHARMACEUTICALS INC | United States | $351.71M | 64,651,693 | 72.52% | 27.48% | Net Selling | Net Selling |
| ABIO | ARCA BIOPHARMA INC | United States | $47.29M | 14,507,143 | 4.98% | 95.02% | ||
| IOBT | IO BIOTECH INC | Denmark | $97.50M | 65,880,914 | 36.62% | 63.38% | Net Buying | Net Selling |
| CYCN | CYCLERION THERAPEUTICS INC | United States | $8.01M | 2,710,096 | 9.83% | 90.17% | Net Buying | |
| CABA | CABALETTA BIO INC | United States | $597.71M | 48,241,615 | 92.00% | 8.00% | Net Buying | |
| RXRX | RECURSION PHARMACEUTICALS INC | United States | $2.07B | 234,653,272 | 75.32% | 24.68% | Net Selling | Net Selling |
| MNKD | MANNKIND CORP | United States | $1.19B | 270,418,215 | 30.01% | 69.99% | Net Buying | Net Selling |
| PHAR | PHARMING GROUP NV | Netherlands | $671.07M | 671,073,243 | 0.00% | 0.00% | ||
| URGN | UROGEN PHARMA LTD | Israel | $487.95M | 34,122,087 | 62.74% | 29.32% | Net Buying | Net Selling |
| ADPT | ADAPTIVE BIOTECHNOLOGIES CORP | United States | $436.73M | 145,092,271 | 62.07% | 37.93% | Net Selling | Net Selling |
Biotech Stocks FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.